REG - Roquefort Theraptcs. - Issue of Equity

Roquefort TherapeuticsAnnouncement

13/06/2025 16:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250613:nRSM8401Ma&default-theme=true

RNS Number : 8401M  Roquefort Therapeutics PLC  13 June 2025

13 June 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Issue of Equity

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on developing first in class medicines in the high value and high
growth immunology and oncology markets, announces the issue of 2,466,547 new
ordinary shares of £0.01 each ("Ordinary Shares") in settlement of amounts
owed to a former employee of the Company ("Settlement Shares").

 

Admission and Total Voting Rights

Application will be made for the Settlement Shares to be admitted to trading
on the London Stock Exchange's Main Market for listed securities, which is
expected to occur on or around 19 June 2025 ("Admission"). The Settlement
Shares will rank pari passu in all respects with the Company's existing
Ordinary Shares.

 

Following Admission, the Company's issued share capital will comprise
157,444,030 Ordinary Shares in issue, with each share carrying the right to
one vote. The Company does not hold any Ordinary Shares in treasury. The
figure of 157,444,030 Ordinary Shares may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or of a change to their interest in the
Company under the FCA's Disclosure and Transparency Rules.

 

Regulatory Information

This Announcement contains inside information for the purposes of the UK
version of the market abuse regulation (EU No. 596/2014) as it forms part of
United Kingdom domestic law by virtue of the European Union (Withdrawal) Act
2018 ("UK MAR").

 

ENDS

 
Enquiries:
 Roquefort Therapeutics plc                               +44 (0)20 3918 8633
 Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
 SP Angel Corporate Finance LLP (Broker)                  +44 (0) 20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 Burson Buchanan (Public Relations)                       +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper
 Peak IR (Investor Relations)                             +33 (0)7 44 44 15 42

 Seb Wykeham

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the
immunology and oncology markets prior to securing a value accretive exit.

 

Roquefort Therapeutics' portfolio consists of five novel patent-protected
pre-clinical anti-cancer and immunology assets.

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEXXLFFEQLFBBV